These compounds were chosen for their ability to counteract the chemoresistance of malignant mesothelioma and other tumor models.25, 26, 27, 28 FACS analysis of the purified, bromodeoxyuridine (BrdU)-labeled CSF-1Rpos cells (from H-2595 and H-2373 cells) revealed that three of the tested compounds were capable of significantly decreasing the growth of the H-2595- and H-2373-derived CSF-1Rpos cells, with the ERK inhibitor showing no effect and the AKT inhibitor the strongest one (Figure 5d and Supplementary Figure 4C). Here, AKT1 is linked to malignant mesothelioma.